<DOC>
	<DOC>NCT01175824</DOC>
	<brief_summary>The study is a comparison of twice-daily insulin lispro low mixture versus once-daily basal insulin glargine and once-daily prandial insulin lispro, in participants with Type 2 Diabetes.</brief_summary>
	<brief_title>Comparison of the Efficacy and Safety of Two Insulin Intensification Strategies</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Present with type 2 diabetes mellitus Have been taking metformin and/or pioglitazone Have received treatment with basal insulin glargine, injected once a day, for greater than or equal to 90 days Have glycosylated hemoglobin A1c (HbA1c) concentration between greater than or equal to 7.5% and less than or equal to 10.5 Have a fasting plasma glucose concentration of less than or equal to 6.7 millimoles per liter [mmol/L, less than or equal to 121 milligrams per deciliter (mg/dL)], or greater than 6.7 mmol/L (greater than 121 mg/dL) if the investigator considers that further titration of basal insulin glargine is not possible for safety reasons Not pregnant or breastfeeding Have Type 1 Diabetes Their stable dose of pioglitazone is greater than the maximum dose approved for use in combination with insulin in their country Have a body mass index (BMI) greater than 45 kilograms per square meter (kg/m2). Have a history of scheduled mealtime (prandial) insulin use within 12 weeks of the screening visit and the total duration of the prandial insulin treatment was greater than 2 weeks Have had more than one episode of severe hypoglycaemia within 24 weeks prior to entry into the study Have cardiac disease with a functional status that is Class III or IV Have a history of renal or liver disease Have had a blood transfusion or have a blood disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Metabolic Diseases</keyword>
	<keyword>Diabetes Mellitus, Type 2</keyword>
	<keyword>Glargine</keyword>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Insulin LISPRO</keyword>
	<keyword>Insulin</keyword>
</DOC>